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Abstract  
 
Background: In 2018, an estimated 2.1 million new cases of breast cancer were detected in women 
worldwide, making it the most commonly diagnosed cancer among females. Skin-Sparing Mastectomy 
(SSM) and Nipple-Sparing Mastectomy (NSM) are surgical treatment options, but are still faced with 
some degree of concern regarding their oncological safety and their immediate complications following 
surgery. In order to add up to already available consecutive case series on the subject, this paper aims 
to give information on the type and rate of immediate surgical morbidity (within 30 days), local tumor 
recurrence and the occurrence of new primary breast cancer following risk-reducing SSM/NSM. 
Methods: Retrospective analysis of clinical files of patients who underwent SSM or NSM with 
immediate breast reconstruction at the BC-CHSJ between January 2011 and December 2015. 
Results: A total of 186 patients underwent SSM or NSM followed by IBR at CHUSJ Breast Centre 
between January 2011 and December 2015.  Of these, 46 underwent double mastectomy, resulting in 
a total of 232 surgical procedures. Overall complication rate was 42,2%, and the rate of grade II/III 
complications using the Clavien-Dindo Classification was 27.1%. Local recurrence rate of breast cancer 
following these procedures was 1.8% over a 56-months (range, 13-93) follow-up. No cases of primary 
tumor following prophylactic surgery were reported. 
Conclusions: The rate of immediate complications with an impact in patient’s clinical course following 
skin-sparing or nipple sparing mastectomy is low. Recurrence rate following these procedures is 
comparable to that of traditional mastectomy and after prophylactic procedures there were no primary 
breast tumors detected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
In 2018, an estimated 2.1 million new cases of breast cancer were detected in women worldwide, 
making it the most commonly diagnosed cancer among females (11.6% of the total cases).1 Breast 
cancer is the leading cause of cancer death among women as well, and its complex approach requires 
a multi-disciplinary team of professionals consisting of oncologic and plastic surgeons, radiologists, 
oncologists, pathologists and expertise of other fields, such as Psychology and Nursing.1,2 
The publishing of the Milan trials in 1981 and the National Surgical Adjuvant Breast and Bowel 
Project (NSABP) B-04 trial in 1985 was considered a landmark, for such projects paved the way for the 
emergence of breast-conserving surgery (BCS)- quadrantectomy or lumpectomy.3,4 These techniques 
are less mutilating than it had been previously assumed to be necessary for breast cancer treatment, 
originating a paradigm shift for the surgical management of breast cancer.3,4 Nowadays, aesthetic 
results are a matter under growing awareness in the management of breast cancer due to the 
psychological effects caused by breast disfigurement.5,6 As a result, despite oncological safety being 
the main focus of treatment, a present-day operation gracefully balances disease control with external 
appearance outcomes, fitting within the concept of oncoplastic surgery.7 Nevertheless, about one-third 
of women with breast cancer still require a mastectomy, either because BCS is declined or due to the 
size, site or extent of the tumor.8 
Skin-Sparing Mastectomy (SSM) and Nipple-Sparing Mastectomy (NSM) are of comparatively 
recent vintage, rising to surface along the lines of the change in the paradigm.9 Indeed, in 1962, Freeman 
introduced a subcutaneous mastectomy for benign breast lesions with immediate or delayed prosthetic 
replacement, and five years later he described its complications.10,11 In order to avoid the complications 
of immediate reconstruction, surgeons then started to adopt a technique in which the nipple would be 
transplanted to the groin and kept there until the final breast reconstruction, which in turn led to reports 
describing the development of infiltrating carcinoma at the transplantation site, bringing about the disuse 
of free nipple grafting in oncologic surgeries by most surgeons for many years.12,13 In 1991, the term 
“skin-sparing mastectomy” was used for the first time by Toth and Lappert, and a few years later, despite 
the opposing views of some analyses, the concept of NSM was revisited in the context of breast surgical 
oncology, after the results of the NSABP B-06 study- a randomized, prospective, multicenter study, with 
20 years of published follow-up- reported no difference in survival among the patients randomized to 
mastectomy, lumpectomy or lumpectomy with radiation therapy.4, 14-19 Jensen points out that safety of 
NSM is sustained on the fact that, in the face of a nipple recurrence, the patient can be treated without 
loss of benefit in survival, and not on the assumption that it is not possible for nipple recurrences to 
occur.20-23 The Oncoplastic Breast Consortium consensus conference panel held in 2018, consisting of 
44 breast surgeons and a patient advocate, regards NSM as a safe procedure, if patients meet the 
recommended criteria and appropriate techniques are performed by a team of specialists.24 
  
On account on some concern still present on the oncological safety of SSM and NSM, and to add 
up to consecutive case series on the subject already available, in addition to characterizing the patients 
who underwent SSM or NSM with immediate breast reconstruction (IBR) in the Breast Centre of São 
João University Hospital (BC-CHSJ) from January 2011 to December 2015, this paper aims to give 
information on the type and rate of immediate surgical morbidity (within 30 days), local tumor recurrence 
and the occurrence of new primary breast cancer following risk-reducing SSM/NSM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
METHODS 
 
Patient and procedure data 
 
All patients who underwent SSM or NSM with IBR at the BC-CHSJ between January 2011 and 
December 2015 were identified using a retrospective surgery chart review. Patients on this chart were 
assigned to SSM or NSM by their physician, based on the diagnosis of breast cancer or the identification 
of oncogenic mutations with increased risk for breast cancer development. SSM was performed if the 
tumor or the suspicious microcalcifications were within a 10mm distance from the nipple. In case they 
were more than 20mm away from the nipple, NSM would be the chosen option. Retroareolar tissue 
frozen section was performed in the cases in which the tumor or the suspicious microcalcifications were 
within a 10-20 mm range from the nipple. In the event of a positive RATFS result, NAC excision was 
performed. The medical files of all selected patients were then retrospectively reviewed, and a database 
was created. 
Collected patient data included age at diagnosis and age at surgery, date of last medical 
observation, weight (kg), height (cm), smoking habits and the need for adjuvant treatments. Regarding 
tumor features, final pathologic stage, histologic grade, the presence of lymphovascular invasion, the 
histological subtype, the status of estrogen receptor (ER), progesterone receptor (PR) and Human 
epidermal growth factor receptor-2 (HER2) protein overexpression were recorded.  ER and PR were 
deemed positive if present in at least 1% of the tumor cells. HER-2 was considered positive in cases of 
IHC +++ or ISH positivity. Tumor staging was performed according to the American Joint Committee on 
Cancer (AJCC) Cancer Staging Manual, 7th Edition. Surgical data included mastectomy technique and 
the reconstruction technique, previous or simultaneous sentinel LN biopsy, and the performance and 
outcomes of retroareolar tissue frozen section (RATFS).  
Immediate surgical morbidity included explantation of prosthesis, hematoma, seroma, partial and 
total nipple/areola necrosis, wound infection, skin flap necrosis, distant flap necrosis (LD, TRAM, DIEP), 
wound dehiscence, rehospitalization and reoperation rates (30 days). Complications were graded 
according to the Clavien-Dindo classification.25 Date and site of first local recurrence (LR) was also 
analyzed.  
After mastectomy, patient’s follow-up differed according to tumor stage: stages 1 and 2 were 
submitted to yearly physical examination, mammography and breast ultrasound; in addition, stages 3 
and 4 performed yearly bone scintigraphy, total CT scan and serum tumor markers measurements (CEA 
and Ca15.3).  
This study was approved by the Ethics Committee of CHUSJ. 
 
 
 
 
 
 
Statistical analysis  
 
Descriptive statistical analysis was performed using IBM SPSS Statistics 24.0 (SPSS Inc., 
Chicago, IL, USA).  
Rate of immediate complications was calculated by dividing the number of procedures in which a 
complication occurred in the 30 days following surgery by the total number of procedures. Rate of LR 
was calculated by dividing the number of recurrences by the total number of procedures with a curative 
purpose. Rehospitalization rate was calculated by dividing the number of individuals who were 
readmitted to the hospital in the next 30 days after surgery by the total number of individuals that 
underwent SSM/NSM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 
Patient and Surgery Characteristics 
 
A total of 186 patients underwent SSM or NSM followed by IBR at CHUSJ Breast Centre between 
January 2011 and December 2015.  Of these, 46 underwent double mastectomy, resulting in a total of 
232 surgical procedures.  
Median age at diagnosis was 48yo (range, 26-80), with a median BMI of 24,7 kg/m2 and a 15.6% 
smoking rate (Table 1). Median waiting time for elective surgery was 47 days (range, 1-2723). The vast 
majority of patients (91,9%) are currently alive with no evidence of cancer. One patient presented with 
synchronous hepatic metastases at primary diagnosis of breast cancer and later died of the disease. A 
large number of patients had stage 0 breast cancer (21,5%), stage 1 cancer (30,6%) or stage 2 cancer 
(22,0%). Among those with invasive cancer, 88,9% and 79,8% showed positivity for estrogen receptors 
and progesterone receptors, respectively, and 16.2% had HER2 protein overexpression. In addition, 
considering that group, the majority underwent adjuvant ChT or endocrine therapy, while only 10,1% 
received radiation therapy.  
 
More than half of surgical procedures were performed with a curative purpose (163, 70,3%), 
whereas 69 (29,7%) presented as a risk-reducing surgery (Table 2). A total of 86 SSM and 146 NSM 
were performed. Only 62 charts clearly stated the adopted surgical excision technique, the most used 
being blade dissection alone (40 procedures). Mixed excision technique were defined as a combination 
of sharp dissection and/or scissors and/or electrocautery.  The most frequent breast reconstruction 
techniques were subpectoral expander (two stages technique, 44,8%) and TRAM-flap (23,3%). 
Surgeons performed 43 RATFS (18,5% of procedures), 10 of which resulted in the detection of a tumor. 
In those cases, the surgeon proceeded to NAC excision.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 1. PATIENT CHARACTERISTICS 
  Total 
(n=232) 
 
SSM 
(n=86) 
NSM 
(n=146) 
 
Curative 
(n=163) 
 
Risk-
reducing 
(n=69) 
 
Median age at diagnosis, 
years  
(n=186) 
 48 
(26-80) 
51 
(35-80) 
46 
(26-68) 
49 
(26-80) 
41 
(26-72) 
Median waiting time, days 
(n=186) 
 47 
(1-2736) 
42 
(2-547) 
52 
(1-2736) 
42 
(1-383) 
95 
(18-2736) 
 
Median follow-up time, 
months 
(n=186) 
 52 
(13-93) 
52 
(13-93) 
55 
(16-91) 
55 
(16-93) 
51 
(13-91) 
Current Status 
(n=186) 
ANED 171 
(91,9%) 
67 
(90,5%) 
104 
(92,9%) 
128 
(92,1%) 
46 
(97,9%) 
 AWC 13 
(7,0%) 
6 
(8,1%) 
7 
(6,3%) 
10 
(7,2%) 
- 
 DOC 1 
(0,5%) 
1 
(1,4%) 
- 1 
(0,7%) 
- 
 DOTHER 1 
(0,5%) 
- 1 
(0,9%) 
- 1 
(2,1%) 
Weight median, kg 
(n=182) 
 63 
(44-93) 
64 
(44-89) 
64 
(45-93) 
64 
(44-89) 
63 
(47-93) 
Height, median, cm 
(n=162) 
 160 
(134-178) 
160 
(134-175) 
161 
(146-178) 
160 
(134-178) 
162 
(142-175) 
BMI, median 
(n=162) 
 24,7 
(16,7-38,1) 
25,3 
 
(17,3-34,3) 
24,1 
(16,7-38,1) 
24,8 
(16,7-34,3) 
24,0 
(17,3-38,1) 
Smoking habits 
(n=186) 
no 115 
(61,8%) 
43 
(58,1%) 
72 
(64,3%) 
87 
(62,6%) 
28 
(59,6%) 
 yes 29 
(15,6%) 
11 
(14,9%) 
12 
(16,1%) 
23 
(16,5%) 
6 
(12,8%) 
 unknown 42 
(22,6%) 
20 
(27,0%) 
22 
(19,6%) 
29 
(20,9%) 
13 
(27,7%) 
Stage of cancer 
(n=186) 
0 40 
(21,5%) 
18 
(24,3%) 
22 
(19,6%) 
40 
(28,8%) 
- 
 1 57 
(30,6%) 
26 
(35,1%) 
31 
(27,7%) 
57 
(41,0%) 
- 
 2 41 
(22,0%) 
18 
(24,3%) 
23 
(20,5%) 
41 
(29,5%) 
- 
 4 1 
(0,5%) 
1 
(1,4%) 
- 1 
(0,7%) 
- 
 NA 47 
(25,3%) 
11 
(14,9%) 
36 
(32,1%) 
- 47 
(100%) 
Tumor grade  
(invasive cancer n=99) 
 
1 28 
(28,3%) 
14 
(31,1%) 
14 
(25,9%) 
28 
(28,3%) 
- 
 2 41 
(41,4%) 
20 
(44,4%) 
21 
(38,9%) 
41 
(41,4%) 
- 
 3 28 
(28,3%) 
13 
(15,1%) 
17 
(31,5%) 
28 
(28,3%) 
- 
 NA 2 
(2%) 
- 2 
(3,8%) 
2 
(2,0%) 
- 
LN metastasis 
(invasive cancer n=99) 
 
no 86 
(86,9%) 
37 
(82,2%) 
49 
(90,7%) 
86 
(86,9%) 
- 
 yes 13 
(13,1%) 
8 
(17,8%) 
5 
(9,3%) 
13 
(13,1%) 
- 
ER 
(invasive cancer n=99) 
 
 
negative 11 
(11,1%) 
4 
(8,9%) 
7 
(13,0%) 
11 
(11,1%) 
- 
 positive 88 
(88,9%) 
41 
(91,1%) 
47 
(87,0%) 
88 
(88,9%) 
- 
PR  
(invasive cancer n=99) 
 
negative 20 
(20,2%) 
6 
(13,3%) 
14 
(25,9%) 
20 
(20,2%) 
- 
 positive 79 
(79,8%) 
39 
(86,7%) 
40 
(74,1%) 
79 
(79,8%) 
- 
HER2 status  
(invasive cancer n=99) 
 
 
negative 81 
(81,8%) 
34 
(75,6%) 
47 
(87,0%) 
81 
(81,8%) 
- 
 positive 16 10 6 16 - 
(16,2%) (22,2%) (11,1%) (16,2%) 
 Undefined 2 
(2,0%) 
1 
(2,2%) 
1 
(1,9%) 
2 
(2,0%) 
- 
Chemotherapy 
(invasive cancer n=99) 
 
no 41 
(41,4%) 
19 
(42,2%) 
22 
(40,7%) 
41 
(41,4%) 
- 
 neoadjuvant 2 
(2,0%) 
- 2 
(3,7%) 
2 
(2,0%) 
- 
 adjuvant 56 
(56,6%) 
26 
(57,8%) 
30 
(55,6%) 
56 
(56,6%) 
- 
Radiation therapy 
(invasive cancer n=99) 
 
no 89 
(89,9%) 
38 
(84,4%) 
51 
(94,4%) 
89 
(89,9%) 
- 
 yes 10 
(10,1%) 
7 
(15,6%) 
3 
(5,6%) 
10 
(10,1%) 
- 
Antihormonal therapy 
(invasive cancer n=99) 
 
 
no 10 
(10,1%) 
2 
(4,4%) 
8 
(14,8%) 
10 
(10,1%) 
- 
 adjuvant 89 
(89,9%) 
43 
(95,6%) 
46 
(85,2%) 
89 
(89,9%) 
- 
ANED= alive with no evidence of cancer, AWC= alive with cancer, BMI= body mass index; DOTHER= died of other reason, 
ER= estrogen receptor, HER2= human epidermal growth factor receptor-2, LN= lymph node, DOC=died of cancer, PR= 
progesterone receptor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 2. SURGERY CHARACTERISTICS 
  Total 
(n=232) 
SSM 
(n=86) 
NSM 
(n=146) 
Curative 
(n=163) 
Risk- 
Reducing 
(n=69) 
 
Mastectomy 
technique 
 
Tumescent technique+ Sharp 
dissection alone 
1 
(0,4%) 
- 1 
(0,7%) 
1 
(0,6%) 
- 
 Blade dissection alone 40 
(17,2%) 
17 
(19,8%) 
23 
(15,8%) 
29 
(17,8%) 
11 
(15,9%) 
 Scissors dissection alone 7 
(3,0%) 
2 
(2,3%) 
5 
(3,4%) 
6 
(3,7%) 
1 
(1,4%) 
 Electric cautery alone - - - - - 
 Mixed technique 13 
(5,6%) 
3 
(3,5%) 
10 
(6,8%) 
10 
(6,1%) 
3 
(4,3%) 
 Unknown 170 
(73,3%) 
22 
(25,6%) 
110 
(75,3%) 
117 
(71,8%) 
54 
(78,2%) 
       
Type of 
reconstruction 
 
Subpectoral TE 104 
(44,8%) 
32 
(37,2%) 
72 
(49,3%) 
59 
(36,2%) 
45 
(65,2%) 
 Prepectoral TE 3 (1,3%) - 3 
(2,1%) 
2 
(1,2%) 
1 
(1,4%) 
 Subpectoral DI 28 
(12,1%) 
4 
(4,7%) 
24 
(16,4%) 
16 
(9,8%) 
12 
(17,4%) 
 Prepectoral DI 3 (1,3%) - 3 
(2,1%) 
- 3 
(4,3%) 
 LD + Implant 19 (8,2%) 12 
(14%) 
7 
(4,8%) 
18 
(11%) 
1 
(1,4%) 
 Skin Graft + Implant 2 (0,9%) - 2 
(1,4%) 
2 
(1,2%) 
- 
 TRAM Flap 54 
(23,3%) 
26 
(30,2%) 
28 
(19,2%) 
49 
(30,1%) 
5 
(7,2%) 
 DIEP Flap 18  
(7,8%) 
12 
(14,0%) 
6 
(4,1%) 
16 
(9,8%) 
2 
(2,9%) 
 LD + Expander 1 (0,4%) - 1 
(0,7%) 
1 
(0,6%) 
- 
DI= Direct to Implant, DIEP= Deep inferior epigastric artery perforator, LD= Latissimus Dorsi, TE= Tissue Expander, TRAM= 
Transverse Rectus Myocutaneous 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immediate complications 
 
Information regarding the morbidity events in the 30 days following surgery was easily available 
in all clinical files, except for one patient’s file, which did not have sufficient data for assessment of 
surgical morbidity. 
Overall complication rate was 42,2%, and the rate of grade II/III complications using the Clavien-
Dindo Classification was 27.1% (Table 3). The most frequent immediate complication after mastectomy 
was the development of a hematoma (12,9%). The vast majority of the patients (72,8%) suffered no 
complications or minor, grade I. Serious complications (e.g., CDC grade III) occurred after 13,8% of 
procedures. Partial and total nipple/ areolar necrosis happened in 14.8% and 8.5% of NSMs, 
respectively.  
Re-hospitalization rate was 5,4% (10/186) and 15,6% of patients were re-operated under general 
anesthesia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 3. IMMEDIATE COMPLICATIONS (30 DAYS) 
  Total 
(n=232) 
SSM 
(n=86) 
NSM 
(n=146) 
Curative 
(n=163) 
Risk-
reducing 
(n=69) 
Immediate Complications       
Explantation of prosthesis  8 
(3,4%) 
4 
(4,7%) 
4 
(12,3%) 
5 
(3,1%) 
3 
(4,3%) 
Hematoma  30 
(12,9%) 
12 
(14,0%) 
18 
(12,3%) 
25 
(15,3%) 
5 
(7,2%) 
Seroma  25 
(10,8%) 
14 
(16,3%) 
11 
(7,5%) 
18 
(11,0%) 
7 
(10,1%) 
Partial nipple/ areolar necrosis  24 
(10,3%) 
- 24 
(16,4%) 
15 
(9,2%) 
9 
(13,0%) 
Total nipple/ areolar necrosis  13 
(5,6%) 
- 13 
(8,9%) 
7 
(4,3%) 
6 
(8,7%) 
Wound infection  10 
(4,3%) 
6 
(7%) 
4 
(2,7%) 
9 
(5,5%) 
1 
(1,4%) 
Skin flap necrosis  20 
(8,6%) 
11 
(12,8%) 
9 
(6,2%) 
15 
(9,2%) 
5 
(7,2%) 
Distant flap necrosis (LD, TRAM, 
DIEP) 
 9 
(3,9%) 
6 
(7,0%) 
2 
(2,1%) 
9 
(5,5%) 
- 
Wound dehiscence  14 
(6,0%) 
10 
(11,6%) 
2 
(2,7%) 
12 
(7,4%) 
2 
(2,9%) 
       
Others       
Rehospitalization (30 days)       
Reoperation under general 
anesthesia 
      
       
Clavien-Dindo Classification       
 0-I 169  
(72,8%) 
58 
(67,4%) 
111 
(76,0%) 
116 
(71,2%) 
53 
(76,8%) 
 II 31  
(13,4%) 
15 
(17,4%) 
16 
(11,0%) 
24 
(14,7%) 
7 
(10,1%) 
 III (A/B) 32  
(13,8%) 
13 
(15,1%) 
19 
(13,0%) 
23 
(14,1%) 
9 
(13,0%) 
  
No Procedures with complications 98 
 
42,2% 
 
27,1% 
 
Overall Complication Rate 
 
Grade II/III Complications Rate 
  
Rehospitalization rate (30 days) 
 
5,4% 
DIEP= Deep inferior epigastric artery perforator, LD= Latissimus Dorsi, TRAM= Transverse Rectus Myocutaneous 
 
 
 
 
 
 
 
 
 
 
 
 
Local recurrence and Primary Tumor after Prophylactic Mastectomy 
 
Three of a total of 163 SSM/NSM with a curative purpose had breast cancer recurrence (Table 
4). Therefore, LR rate of breast cancer following these procedures was 1.8% over a 56-months (range, 
13-93) follow-up. The median time from treatment to LR was 36 months (mean, 36,7; range, 29-45).  
In 2011, patient A underwent bilateral NSM with IBR with expanders and subsequent adjuvant 
ChT (FEC) and HT (tamoxifen) for a right breast primary tumor. Definitive 355cc implants placed in 2012 
were later switched to 435cc implants in 2015, both procedures followed one year later by breast 
augmentation by lipofilling. In 2017, this patient underwent total mastectomy of the right breast and 
sentinel LN biopsy. Pathology described a multifocal in-breast recurrence (4 foci, sized from 8 to 14 
mm). Then, Patient A received ChT (TC*6), thoracic wall RT and HT (exemestane).  
Patient B underwent NSM of the left breast with IBR with DIEP flap in 2011, followed by adjuvant 
ChT (FEC) and HT (tamoxifen). Subcutaneous LR was diagnosed in 2015, and prompted a tumorectomy 
plus sentinel node biopsy, and adjuvant breast RT and HT with anastrozole. 
In January 2015, patient C was diagnosed with a 9mm tumor in the right breast. This patient had 
a 16,8 kg/m2 BMI and an A breast cup. NSM with IBR with a 245cc implant took place in February 2015, 
and a week later patient was re-operated due to hematoma and maintained the implant. This patient 
received 2 cycles of adjuvant TC and later switched to 4 cycles of AC due to multiple systemic reactions 
to TC.  In 2016, implant was switched to a 320 cc one and a lipofilling was performed. In 2017, excision 
of a cutaneous node on the mastectomy scar revealed a local tumor recurrence. This resulted in a total 
mastectomy and adjuvant chest wall RT and 8 cycles of capecitabine. 
No cases of primary breast cancer were detected after prophylactic mastectomy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 4. PATIENTS WITH LOCAL RECURRENCE  
 PT:  
Site, Surgery, Characteristics and 
Adjuvant therapy 
PT treatment-to-
recurrence 
interval 
Recurrence: 
Site, Surgery, Treatment 
CS and 
Follow-up 
time 
Patient 
A 
UOQ, NSM with underpectoral expander, 
Multifocal Mixed tumor (ductal and 
mucinous).  
HR+ (>80%), Her2- 
pT2 (14mm) N0sn M0 G3 R0 
ChT+HT+RT 
73 months UOQ, Subcutaneous/ in-
breast,  
Total Mastectomy (including 
reconstruction) 
ChT+RT+HT 
 
 
ANED 
92 months 
Patient 
B 
UIQ, NSM with DIEP flap, 
Unifocal NST carcinoma.  
HR+ (>90%) HER2- 
pT2 (22mm) N0sn M0 G2 R0 
ChT+ HT 
44 months UIQ, Subcutaneous/ in-
breast, Wide Excision +  
RT+ HT 
 
ANED 
82 months 
Patient 
C 
UIQ, NSM with underpectoral implant, 
Unifocal Basal cell carcinoma 
HR- Her2- 
pT1 (8mm) N0sn M0 G3 R0 
ChT+ RT 
28 months UIQ, Cutaneous (Surgical 
Scar), 
Total Mastectomy (including 
reconstruction) 
RT + ChT 
ANED 
54 months 
CS= Current Status, ChT= Chemotherapy, HT= hormonal therapy, NST= No special type, PT= Primary Tumor, RT= 
Radiotherapy, UIQ= Upper-Inner Quadrant of breast cancer UOQ= Upper-Outer Quadrant of breast cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 DISCUSSION 
 
Authors of this study carried out a retrospective review of patient’s clinical files to examine the 
complications and the oncological safety of SSM/NSM with IBR. In skin-sparing mastectomy, the breast 
glandular tissue is removed and separated from the subcutaneous fat, but most of the breast skin is 
retained.9 Nipple-sparing mastectomy is in essence the same process, with the exception of the 
conservation of the nipple-areolar complex.9 During the surgery, in case the retroareolar tissue sent for 
frozen pathology reports the presence of a tumor, the surgeon proceeds to excision of the nipple areolar 
complex.2 
 
Immediate complications associated with the analyzed conservative mastectomies included 
breast prosthesis explantation, hematoma, seroma, wound infection or dehiscence, necrosis (nipple, 
skin-flap, or distant flap necrosis). Rehospitalization and reoperation under general anesthesia were 
also taken into account in this analysis. The overall complication rate was 42,2%. However, considering 
the complications that authors of this study find to have a bigger impact on patient’s well-being and 
clinical course (eg Clavien-Dindo grade II/III complications), this rate was 27,1%, which is close to those 
reported in literature.26 Nipple necrosis rate was 15,9%. A systematic review of the literature from 
Headon et which included 12 358 NSMs and revealed an overall complication rate of 22.3% and overall 
incidence of partial or total nipple necrosis of 5.9%.26 Partial or full nipple necrosis is reported in 2% to 
20% of cases after NSMs.27 Headon et al. suggested that factors that influence the occurrence of nipple 
necrosis were breast features (large size and ptosis), periareolar incision, tobacco use and re-exposure 
to radiotherapy.26  
  
Local recurrence rate of breast cancer following skin-sparing or nipple-sparing mastectomy with 
immediate breast reconstruction was 1.8% over a 56-months follow-up. This indicates that these 
procedures present as an oncologically safe option for patients that meet the criteria for such 
procedures. Earlier studies reviewed SSM with IBM and found LR rates equivalent to those of total 
mastectomy and that ranged from 0% to 8.3%.5, 28-31 Likewise, De La Cruz et al. authored a meta-
analysis and systematic review that included 5594 patients and concluded that NSM and SSM was not 
associated with higher LR rates compared to modified radical mastectomy.32 In fact, Mota et al states 
describes that after a traditional mastectomy, there is a 2.3% likelihood after 20 years of breast cancer 
having a LR.33  Several factors influence the risk of LR after SSM/NSM, including T2/T3 cancer, triple 
negative tumors, high-grade tumors and positive lymph nodes.31 Vaughan et al. reported that 82% of 
patients had local recurrence in the same area as the primary tumor.30 This work had similar findings. 
Specifically, LR mainly occurred subcutaneously and one cutaneous recurrence, and the area of 
recurrence was the same as that of the primary tumor.  
The greatest limitation of this study was the quality of the reporting of complications following 
mastectomy. Each physician adopted different ways of writing patient’s reports, and its interpretation 
may have affected the results. The nearly five-year follow-up is also a limitation, and future studies with 
longer follow-ups are advised for better assessment of oncologic outcomes of NSM/ SSM. 
This study found no cases of primary breast cancer after risk-reducing NSM/SSM. A systematic 
review published by Carbine et al. reports that both bilateral and contralateral risk-reducing 
mastectomies are effective in reducing the incidence of breast-cancer, but recommend the future 
publications of more prospective studies. 
 
In view of these data, the results of this work suggest that SSM and NSM with immediate breast 
reconstruction present as a feasible option for patients that meet the indication criteria in regards to 
oncological safety and immediate complications.24  
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